The Genomic Atlas of Breast Cancer — the non-coding theme

Update News

  • GABC update 2020.06.15
  • GABC update 2019.03.20
  • GABC online 2018.08.09
  • Data collection 2018.04.09

About Us

  • Steven Xi Chen:
    steven.chen@miami.edu
  • Yunpeng Zhang:
    YXZ1418@med.miami.edu
  • Peng Wang:
    wpgqy@163.com
  • Shangwei Ning:
    ningsw@ems.hrbmu.edu.cn
  • Xia Li:
    lixia@hrbmu.edu.cn

Detail


Chr chr12
start 95308420
end 95308513
ID MI0000812
miRNA_name hsa-miR-331
methods qRT-PCR,etc.
regulated up
Function Description Results:Of 4 miRNA targets tested (miR-181a, miR-329, miR-331, miR-195), mir-331 was significantly over-expressedin patients with metastatic disease, compared to patients with local disease (p< 0.001) or healthy controls(p < 0.001). miR-195 was significantly under-expressed in patients with metastatic disease, compared to patientswith local disease (p < 0.001) or healthy controls (p= 0.043). In combination, miR-331 and miR-195 produced anAUC of 0.902, distinguishing metastatic from local breast cancer.Conclusions:We identified and validated two circulating miRNAs differentiating local Luminal A breast cancersfrom metastatic breast cancers. Further investigation will reveal the molecular role of these miRNAs in metastasis,and determine if they are subtype specific. This work demonstrates the ability of circulating miRNA to identifymetastatic disease, and potentially inform diagnosis or treatment effectiveness.
PMID 31077182
year 2019
Title Circulating microRNAs miR-331 and miR-195 differentiate local luminal a frommetastatic breast cancer
drug X
circulating V
survival X

CopyRight © University of Miami, USA; Harbin Medical University, China